# PSA Biochemical Response as Prognostic Factor in Metastatic Castration-Sensitive Prostate Cancer

> **NCT06652607** · — · RECRUITING · sponsor: **Fondazione Policlinico Universitario Agostino Gemelli IRCCS** · enrollment: 152 (estimated)

## Conditions studied

- Prostate Cancer
- Metastatic Cancer
- Castrate Sensitive Prostate Cancer

## Interventions

- **DRUG:** Enzalutamide
- **DRUG:** Apalutamide (Erleada™) 60 mg or 240 mg tablets
- **DRUG:** Darolutamide (Nubeqa®) 300 mg tablets
- **DRUG:** Taxotere (docetaxel)
- **DRUG:** Abiraterone acetate + Prednisone or Prednisolone

## Key facts

- **NCT ID:** NCT06652607
- **Lead sponsor:** Fondazione Policlinico Universitario Agostino Gemelli IRCCS
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-20
- **Primary completion:** 2026-11-01
- **Final completion:** 2028-04-30
- **Target enrollment:** 152 (ESTIMATED)
- **Last updated:** 2025-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06652607

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06652607, "PSA Biochemical Response as Prognostic Factor in Metastatic Castration-Sensitive Prostate Cancer". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT06652607. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*